Loading organizations...
Taiho Ventures operates as the corporate venture arm of Taiho Pharmaceutical Co., Ltd., strategically investing in early-stage private biotech companies. The firm focuses its investments across oncology, allergy and immunology, and urology, aligning with its parent company’s core therapeutic areas. Beyond direct equity stakes, Taiho Ventures actively engages in company creation, spinouts, and option-type investments to foster innovative scientific advancements.
Sakae Asanuma established Taiho Ventures as its founding President in 2016, drawing on a distinguished career in venture capital and executive management. Prior to this role, Mr. Asanuma served as President and CEO of Astellas Venture Management and US Head of Astellas Innovation Management from 2011 to 2015, and previously worked at the VC firm Yasuda Enterprise from 2000 to 2011. His foundational insight centered on strategically integrating external innovation with established pharmaceutical development.
Taiho Ventures primarily serves innovative biotech companies seeking capital and strategic partnership, ultimately benefiting patients through advanced therapeutic options. The firm's overarching vision is to contribute to a society enriched by improved human health, reflecting the broader mission of Taiho Pharmaceutical. It continues to identify and support global ventures that promise to deliver significant medical breakthroughs.
Key people at Taiho Ventures.
Key people at Taiho Ventures.
Taiho Ventures is the strategic corporate venture capital arm of Taiho Pharmaceutical Co., Ltd., focused on investing in early-stage biotech companies primarily in oncology and related life sciences sectors. Its mission is to create significant value by supporting innovative first-in-class drug discovery and unique platform technologies globally, aligning with Taiho Pharmaceutical’s corporate growth strategy. Since its founding in 2016, Taiho Ventures has built a portfolio of over 25 companies, including notable names like Arcus Biosciences and Orna Therapeutics, and recently expanded its investment pool to $400 million to accelerate open innovation and quality investments[1][4].
Founded as a subsidiary of Taiho Pharmaceutical, a leading Japanese specialty pharma company known for oncology, allergy, and immunology products, Taiho Ventures operates out of Menlo Park, California. The firm was established to leverage Taiho Pharmaceutical’s expertise and global R&D efforts by investing in promising startups worldwide, focusing on early-stage preclinical oncology and platform technology companies. This strategic venture capital arm has evolved to broaden its scope beyond oncology to include modalities such as biologics and small molecules, reflecting a dynamic investment philosophy that embraces diverse innovative approaches in drug development[1][2].
Taiho Ventures rides the growing trend of corporate venture capital in biotech, particularly in oncology, where precision medicine and novel therapeutic modalities are rapidly advancing. The timing is crucial as the biotech sector experiences a surge in platform technologies, gene editing, and immuno-oncology, all areas Taiho Ventures targets. By bridging startup innovation with established pharma capabilities, Taiho Ventures influences the ecosystem by accelerating drug discovery pipelines and fostering open innovation models that benefit both startups and the pharmaceutical industry at large[1][4].
Looking ahead, Taiho Ventures is poised to deepen its impact by leveraging its expanded $400 million fund to back more transformative biotech startups. Trends such as personalized medicine, AI-driven drug discovery, and novel biologics will likely shape its investment focus. As Taiho Pharmaceutical continues its global R&D expansion, Taiho Ventures’ role as a strategic innovation partner will grow, potentially increasing its influence in shaping next-generation oncology treatments and platform technologies worldwide[1][4]. This positions Taiho Ventures as a critical bridge between cutting-edge biotech innovation and global pharmaceutical development.
Taiho Ventures has more than 26 tracked investments across 19 companies. The latest tracked deal is $77.0M Series B in Crossbow Therapeutics in March 2026.
